Elysium Therapeutics

Elysium Therapeutics

Biotechnology, Akron, Ohio, United States, 1-10 Employees

elysiumrx.com

  • twitter
  • LinkedIn

phone no Phone Number: 92********

Who is ELYSIUM THERAPEUTICS

Elysiums mission is to reduce suffering from severe acute pain, opioid-use disorder (OUD), and fatal opioid overdose by developing first- or best-in-class products with profiles that addr...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from ELYSIUM THERAPEUTICS

Elysium Therapeutics Org Chart and Mapping

Alex Sturmer

President, Chief Executive Officer, and Co-Founder

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Elysium Therapeutics

Answer: Elysium Therapeutics's headquarters are located at Akron, Ohio, United States

Answer: Elysium Therapeutics's phone number is 92********

Answer: Elysium Therapeutics's official website is https://elysiumrx.com

Answer: Elysium Therapeutics's revenue is $1 Million to $5 Million

Answer: Elysium Therapeutics's SIC: 2834

Answer: Elysium Therapeutics has 1-10 employees

Answer: Elysium Therapeutics is in Biotechnology

Answer: Elysium Therapeutics contact info: Phone number: 92******** Website: https://elysiumrx.com

Answer: Elysiums mission is to reduce suffering from severe acute pain, opioid-use disorder (OUD), and fatal opioid overdose by developing first- or best-in-class products with profiles that address the key limitations and dangers associated with opioids used today. Our pipeline consists of 3 diverse platforms with broad applicability across several areas of significant unmet need: Technologies 1. O2PTM (Oral Overdose Protection) Lead platform Traditional opioids are easy to abuse, with euphoria and risk of respiratory depression increasing with every pill consumed. O2P provides self-limiting exposure to active opioid and prevents overdose. 2. XpiRxTM (Forced Expiration) 70-year half-life of traditional opioids creates a surplus supply of readily available pills that can end up on the streets. XpiRx opioids, whose potency expires after the prescribed-use period, reduce abuse and prevent fatal overdoses. 3. SOOPRTM (Synthetic Opioid Overdose Prevention and Rescue) Existing rescue agents are too short-acting and weak against synthetic opioids, often requiring multiple doses. SOOPR lasts up to 24 hours and is more effective against synthetic opioids (e.g., fentanyl, nitazenes) than todays standard-of-care Elysium has a highly attractive risk/reward profile: 1. High-probability of Success: In vitro and in vivo proof-of-concept data for its new chemical entities that are comprised of FDA-approved drugs 2. Capital Efficiency: Leveraging non-dilutive grant funding, ~$16M to-date 3. Platform Opportunity: Diversified portfolio of programs addressing the key underlying factors that are driving the opioid crisis and could yield multiple products within 3-5 years 4. Market: Multi-billion-dollar market potential, with weak direct pipeline competition 5. Intellectual Property: Strong protection, with issued patents in the US and internationally, including composition of matter

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access